- Home
- GALT vs IMUX Comparison
GALT vs IMUX Comparison
Compare GALT & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GALT | IMUX |
|---|---|---|
| Founded | 2000 | 2016 |
| Country | United States | United States |
| Employees | 9 | 66 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 297.0M | 200.4M |
| IPO Year | 2008 | 2013 |
Fundamental Metrics
Financial Performance| Metric | GALT | IMUX |
|---|---|---|
| Price | $4.63 | $14.86 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | $8.50 | ★ $36.00 |
| AVG Volume (30 Days) | ★ 1.1M | 195.3K |
| Earning Date | 05-15-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 36.84 | ★ 38.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.03 | $0.51 |
| 52 Week High | $7.13 | $15.84 |
Technical Indicators
Market Signals| Indicator | GALT | IMUX |
|---|---|---|
| Relative Strength Index (RSI) | 72.46 | 60.93 |
| Support Level | $2.75 | $0.74 |
| Resistance Level | $5.21 | $15.81 |
| Average True Range (ATR) | 0.47 | 0.88 |
| MACD | 0.14 | -0.13 |
| Stochastic Oscillator | 80.23 | 58.33 |
Price Performance
Historical ComparisonAbout GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
About IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.